Resonac Holdings (4004.T) — Graham Screen #

Layer: L0-Materials | Date: 2026-05-28 | Analyst: ACE

PRICE SNAPSHOT #

Screen path determination: YTD >80% AND within 10% of 52W high → abbreviated criteria met. However: the re-rating from JPY 3,037 to JPY 18,500 in 12 months is a genuine fundamental re-rating (no stock split confirmed), driven by semiconductor cycle acceleration. A truncated screen would miss the structural thesis question. Full screen executed because the core thesis question — "has it fully rerated or is there residual value?" — cannot be answered without segment-level data.

COMPANY OVERVIEW #

Resonac Holdings Corporation (formerly Showa Denko K.K., renamed January 2023 after absorbing Hitachi Chemical in 2021 for ~JPY 960B) is a Japanese diversified chemicals and materials company. The acquisition doubled revenue but loaded the balance sheet with ~JPY 1T in debt.

Segments (FY2025 actual revenue / core operating profit):

The critical asymmetry: Semiconductor = 40% of revenue but 89% of total core operating profit. The rest of the business (60% of revenue) contributes only 11% of profits — and actively destroys value in Chemicals (-5.5B COP loss).

SECTION 1: FINANCIAL METRICS #

Earnings History (FY2021–FY2025) #

Note: IFRS operating income in FY2025 fell to 46.7B vs 89.0B in FY2024 due to amortization charges and one-off items. Core operating income (management metric, excludes PPA amortization) was 109.1B in FY2025 (+18.5% YoY) and is the more meaningful operational measure given the Hitachi-Chem acquisition overhang.

Cash Flow (FY2022–FY2025) #

CapEx jumped in FY2025 to JPY 106.7B — semiconductor capacity investment. Over 50% of OCF allocated to semiconductor growth. FCF thinning as CapEx rises; this is intentional investment-led dilution of near-term FCF.

SECTION 2: BALANCE SHEET & NET DEBT #

Leverage Trajectory #

Key observations:

• Gross debt declining steadily: -JPY 105B since 2022 peak
• ND/EBITDA is volatile (peaked 8.64x in EBITDA-trough year 2023) — a shr-017 cyclical trap warning for trough-based screening
• Company targets ND/EBITDA <3.0x and ND/Equity <1.0x; currently ND/Equity at 0.79x (target achieved), ND/EBITDA at 4.53x (target not yet achieved)
• At FY2026 guided EBITDA (~JPY 210-220B estimate), ND/EBITDA approaches 3.2-3.4x — within striking range of target by FY2027 if semiconductor cycle holds

Goodwill & Intangibles: JPY 410.7B in "other intangible assets" (Hitachi-Chem PPA), no goodwill shown separately as of FY2025 — likely fully amortized or reclassified. Tangible book value only JPY 288.1B vs total equity JPY 698.9B. The intangible-heavy balance sheet is a structural artifact of the acquisition.

SECTION 3: SEMICONDUCTOR SEGMENT DEEP DIVE #

Products #

• CMP Slurries: Chemical Mechanical Planarization — critical consumables for advanced logic/memory nodes. Resonac is top-3 globally (alongside Cabot, CMC Materials)
• Packaging Materials: IC substrates, encapsulants, bonding films — AI accelerator back-end boom driver
• Semiconductor Gases/Solvents: Process gases, etchants
• Hard Disk Media: HDD capacity expansion (still relevant for AI data center storage)
• Lead Frames, Films: Mid-end packaging

Recent Performance (shr-003 growth rate test) #

• FY2024: COP JPY 73.7B
• FY2025: COP JPY 108.4B (+47% YoY)
• Q1 FY2026: COP JPY 34.0B (+74% YoY, record quarterly high)
• FY2026 segment forecast: Revenue JPY 570B (+13%), COP JPY 128B (+18%)

The AI back-end materials demand cycle is real and accelerating. Advanced packaging (CoWoS, SoIC, HBM stacking) requires significantly more bonding films, encapsulants, and specialty adhesives per die than conventional packaging. Resonac is a direct beneficiary.

Concern: Share vs. Commodity Chemicals #

The semiconductor segment's 21.4% COP margin in FY2025 (vs 1-2% margins in Mobility/Chemicals) means the stock is really a bet on: (1) semiconductor materials market share growing faster than the cycle, and (2) petrochem drag shrinking via divestiture. Both conditions appear to be happening, but at valuation 115x trailing / 43.5x forward, the market has already priced this transition far into the future.

SECTION 4: DIVESTITURE & RESTRUCTURING #

Cluster Chemicals (Crasus Chemical) Spin-Off #

• Status: Listing application filed; shareholder approval of constitutional amendments obtained (Q1 2026)
• Expected: Partial spin-off (listed) within calendar year 2026
• Revenue impact: Removes JPY ~300B/yr revenue (24% of total) but only JPY 4.7B COP (4% of total)
• Pro-forma without Cluster Chems: COP margin improves from 9.8% → ~12%, EBITDA margin 21.6% (already at target)
• Debt allocation: Portion of net debt likely to transfer with Crasus entity — could structurally reduce Resonac's ND/EBITDA ratio meaningfully at spin-off

This is the key catalyst that, if completed, transforms Resonac from "chemicals/materials conglomerate" into a semiconductor-heavy specialty materials company with significantly better margins. The market appears to be partly pricing this in given the 6x re-rating.

FY2026 H1 Guidance Raise #

H1 FY2026 guidance raised to JPY 74B core operating profit (+40% from prior guidance), driven by semiconductor materials. Full-year maintained at JPY 105B (implying only JPY 31B in 2H — very conservative). Management cited Middle East geopolitical risk for Crasus Chemicals as reason for full-year conservatism.

SECTION 5: GRAHAM 7 FILTERS #

GRAHAM SCORE: 1/7

This is a failing score by every Graham defensive metric. Note (shr-017): the failure is not a cyclical trap artifact — even FY2024 peak EPS of JPY 407 gives trailing P/E of ~45x and P/B of 4.72x fails regardless. The stock is priced as a growth/transformation story, not as a defensive value situation.

SECTION 6: GRAHAM INTRINSIC VALUE SENSITIVITY TABLE #

Formula: V = EPS × (8.5 + 2g) × (4.4 / Y), where Y = Japan bond proxy Using Y = 1.5% (JGB 10yr) as base; Y = 2.0% as conservative.

Using Trailing EPS JPY 160 (FY2025 actual) #

Trailing EPS is depressed (FY2025 net income fell 60% YoY on one-off charges). Price only justified at g=15% on trailing basis — unrealistic per shr-017 cyclical trap warning.

Using Forward EPS JPY 425 (company-guided FY2026 net profit JPY 77B / 181M shares) #

Using Analyst Consensus EPS JPY 457 (FY2026 consensus) #

Break-even Growth Rate (at JPY 18,500) #

• Forward EPS JPY 425, Y=1.5%: break-even g = 3.2%/yr
• Forward EPS JPY 425, Y=2.0%: break-even g = 5.6%/yr

Interpretation (shr-003): The market is NOT pricing explosive growth at current price. Using forward EPS at Japan's bond rate, the price is justified with only 3-4% sustained EPS CAGR. However: forward EPS of JPY 425 assumes a large FY2025→FY2026 EPS jump (160→425, +166%) already materializing. The question is whether this is sustainable, not just a one-cycle bounce.

Implied growth from P/E (shr-003):

• Trailing P/E 115x → implied g = 53.4%/yr (ridiculous — confirms trailing EPS is distorted)
• Forward P/E 43.5x → implied g = 17.5%/yr (substantial but not absurd for AI materials inflection)
• Gap = 36ppt — the market is pricing a massive, rapid profitability improvement, and Q1 FY2026 data (+74% COP YoY) suggests this inflection is already happening

SECTION 7: SHR-020 RED FLAG CHECK #

Aggregate: 2 RED, 1 AMBER, 3 GREEN, 1 NEUTRAL — the reds are about price and debt, not thesis deterioration.

SECTION 8: KEY RISKS #

1. Valuation has run ahead of fundamentals. At JPY 18,500, the Graham framework says "fair value only at 3-5% sustained CAGR using FY2026 guidance." The stock is no longer deeply discounted; it is fairly to modestly valued on a growth basis.

2. Semiconductor cycle risk. Semi materials demand is AI-driven (advanced packaging, HBM). If AI capex cycle slows, Resonac's 40%-of-revenue / 89%-of-profits semiconductor segment is directly impaired. Unlike ASML/TSMC, Resonac is a consumables supplier — demand collapses quickly when fab utilization drops.

3. Net debt remains elevated. ND/EBITDA 4.53x (above company's own 3.0x target). FY2025 EBITDA was lower than FY2024 (156B vs 199B) despite semiconductor strength, because Chemicals/Crasus dragged. If next cycle turns, EBITDA could compress while debt is sticky.

4. Crasus spin-off execution risk. Partial listing of petrochem business is in progress but not complete. If market reception is poor or spin-off is delayed, the conglomerate discount persists.

5. CapEx escalation. FY2025 CapEx JPY 106.7B (+21% vs FY2024), targeting >JPY 300B over 3 years into semiconductor. If semiconductor cycle weakens mid-investment, FCF could go negative while debt remains high.

6. Analyst consensus BELOW current price. Median PT JPY 15,135, mean PT JPY 14,243 — both 18-23% below current price. The stock has rallied past what most analysts model; either analysts are lagging (likely, given the velocity of the move) or the price has overshot.

SECTION 9: POSITION SIZING CONTEXT #

• Available satellite capital vs EUR 3,000 budget: approximately EUR 833 remaining
• Price per share: JPY 18,500 = EUR 113 at 163 EUR/JPY
• Practical lot at EUR 500 ticket: ~4 shares
• Exchange: Tokyo Stock Exchange (TSE) — not directly accessible via DEGIRO standard account
  • DEGIRO does offer TSE access but requires checking account tier
  • Alternatively available via SHWDY (OTC Pink, unsponsored ADR) — but very low liquidity, not suitable

VERDICT #

Summary Assessment #

Has it rerated? YES, completely. The stock went from JPY 3,037 (May 2025) to JPY 18,500 (May 2026) — a 509% move in 12 months. This is not a missed-value situation; it is a completed re-rating. The market recognized Resonac as a semiconductor materials transformation story and repriced accordingly.

Is petrochemicals cycle keeping it depressed? PARTIALLY. The Chemicals segment is still loss-making (-5.5B COP in FY2025) and Cluster Chemicals (petrochem) generates minimal profit at 1.6% margin. These drag on headline EPS and valuation metrics. The Crasus spin-off, when executed in 2026, will remove this drag and potentially trigger a further re-rating of the remaining "pure" semiconductor materials business.

Graham value? No. Score 1/7. P/B 4.72x, trailing P/E 115x, two net losses in past five years, ND/EBITDA 4.53x. This is a growth/transformation story priced as such — not a Graham defensive investment.

Growth stock addendum (shr-004)? Using forward EPS and Y=1.5%, the price is fair at g=3.2% break-even. The implied growth rate from forward P/E is ~17.5%/yr — the market expects ongoing semiconductor materials outperformance, not just a one-year bounce. This is plausible given AI back-end packaging demand, but the bar has risen dramatically since the re-rating.

For the existing EUR 3,000 satellite portfolio: The stock does not fit the Graham value framework. It is a growth/transformation play, currently trading above analyst consensus price targets, with elevated leverage, and after a 6x move. The EV per EUR deployed (shr-018) is uncertain and time-dependent on the Crasus spin-off executing cleanly. No position recommendation at current price.

Watch level: If a semiconductor correction or Crasus spin-off disappointment brought the price to JPY 10,000-12,000 range, the forward EPS framework would show 40-55% margin of safety at g=5% — that would be an interesting entry. At current levels, the margin of safety is absent under any reasonable scenario except sustained high-teen EPS CAGR.

VERDICT LINE: 🔴 NO ENTRY — Re-rated fully; P/B 4.72x, trailing P/E 115x, forward P/E 43.5x, ND/EBITDA 4.53x, analyst consensus 23% BELOW current price. Strong semiconductor transformation thesis (89% of profits from 40% of revenue; Crasus spin-off progressing; AI back-end materials boom confirmed by Q1 FY2026 +74% COP YoY) is real but fully discounted at JPY 18,500. Graham score 1/7. Watch at JPY 10,000-12,000 (forward EPS JPY 425+ at that price → 40-55% MoS at g=5%, Y=2.0%). #

Sources: yfinance (price/financials), Resonac FY2025 Earnings Briefing (Feb 13, 2026), Resonac Q1 FY2026 Results (May 13, 2026), analyst consensus data via investing.com/yfinance. Data as of 2026-05-28.